Assistant Professor, Comprehensive Cancer Center, Yale University School of Medicine
Hematology
Gina Chung works in the field of Hematology. She attended Stanford University School of Medicine. Stanford University School of Medicine is a top medical university. Stanford University School of Medicine is ranked 2 in research and 25 in primary care medicine She received 1 awards: "CMS Meaningful Use Stage 1 Certification". Gina G. Chung, MD is a published doctor. She has 35 publications published. The most current publication "Patient preferences regarding incidental genomic findings discovered during tumor profiling." Gina G. Chung, MD accepts all Medicare patients.
Publications
- Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-po...
- Systematic approach to providing breast Cancer survivors with survivorship care plans: a feasibility study.
- Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast Cancer after progression on prior trastuzumab therapy.
- Where does radioimmunotherapy fit in the management of breast Cancer?
- Exercise improves body fat, lean mass, and bone mass in breast Cancer survivors.
- Preoperative chemotherapy decreases the need for re-excision of breast Cancers between 2 and 4 cm diameter.
- Tissue microarray analysis of 560 patients with colorectal adenoCarcinoma: high expression of HuR predicts poor survival.
- Randomized controlled trial of aerobic exercise on insulin and insulin-like growth factors in breast Cancer survivors: the Yale Exercise and Survivorship study.
- High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast Cancer.
- Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast Cancer.
- Recruiting and retaining breast Cancer survivors into a randomized controlled exercise trial: the Yale Exercise and Survivorship Study.
- Biomarker validation: in Situ analysis of protein expression using semiquantitative immunohistochemistry-based techniques.
- Quantitative analysis of estrogen receptor heterogeneity in breast Cancer.
- Bimodal population or pathologist artifact?
- Quantitative analysis of breast Cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.
- Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast Cancer.
- Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic Cancer tissue microarray.
- beta-Catenin and p53 analyses of a Breast carcinoma tissue microarray.
- Automated subCellular localization and quantification of protein expression in tissue microarrays.
- Subjective differences in outcome are seen as a function of the immunohistochemical method used on a colorectal Cancer tissue microarray.
- Feasibility of institutional registry-based recruitment for enrolling newly diagnosed breast Cancer patients in an exercise trial.
- Evaluation of vascular endothelial growth factor as a prognostic marker for local relapse in early-stage breast Cancer patients treated with breast-conserving therapy.
- Breast sentinel lymph node dissection before preoperative chemotherapy.
- PMCA2 regulates apoptosis during mammary Gland involution and predicts outcome in breast cancer.
- Exercise and quality of life during and after treatment for breast Cancer: results of two randomized controlled trials.
- Tissue microarray analysis of beta-catenin in colorectal Cancer shows nuclear phospho-beta-catenin is associated with a better prognosis.
- Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic Cancer.
- Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
- Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast Cancer.
- Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with adva...
- Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast Cancer.
- Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for hig...
- Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast Cancer.
- Patient preferences regarding incidental genomic findings discovered during tumor profiling.
Schools
Stanford University
Yale University School Of Med
Yale New Haven Hospital
Procedures Preformed
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Breast Cancer
- Carcinoma in Situ
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Yale-New Haven Hospital
-
Stanford University School of Medicine
Hospital
-
Yale-New Haven Hospital
Drug Facts
| NPI NUMBER |
|
1861480543 |
| NPPES Provider LastName |
|
CHUNG |
| NPPES Provider FirstName |
|
GINA |
| NPPES Provider ZIPCode |
|
065191369 |
| NPPES Provider State |
|
CT |
| Specialty Description |
|
Medical Oncology |
| Total Claim Count |
|
157.0 |
| Distinct Opioid Count |
|
0.0 |
| Opioid Claim Count |
|
0.0 |
| Percent Opioid Claims |
|
0.0 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1861480543 |
| Last Name Of The Provider |
CHUNG |
| First Name Of The Provider |
GINA |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.